Theisen M
Meristem Therapeutics, Clermont-Ferrand, France.
Adv Exp Med Biol. 1999;464:211-20. doi: 10.1007/978-1-4615-4729-7_16.
The production of recombinant proteins for therapeutic use in transgenic plants has become an alternative to the isolation of these molecules from natural or other recombinant sources. Plant bioreactors offer the possibility of an inexpensive large scale production of high volumes of recombinant proteins with increased safety concerning contaminations with human pathogens. Several laboratories are involved in the commercial production of the first recombinant products, such as antibodies or recombinant human hemoglobin, from transgenic plants.
利用转基因植物生产用于治疗的重组蛋白，已成为从天然或其他重组来源分离这些分子的一种替代方法。植物生物反应器提供了一种廉价大规模生产大量重组蛋白的可能性，同时在人类病原体污染方面具有更高的安全性。几个实验室正在参与从转基因植物中商业化生产首批重组产品，如抗体或重组人血红蛋白。
